RxDoctor Payments Data

Augusta Essuman-Nelson, DO

Internal Medicine · Atlanta, GANPI 1558927707

Payments from drug & device makers

$4,418in general payments, 2019–2025

Across 200 payments — averaging $22.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Viiv Healthcare Company$659
  • Gilead$629
  • Novo Nordisk$601
  • Lilly USA, LLC$547
  • Merck$319
  • Pfizer$198
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$4,418100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,418 in reported general payments places this provider in the 85th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$20,941
Medicare patients
83
Services billed
318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$35,301
JanuviaSitagliptin Phosphate26$22,496
JanumetSitagliptin Phos/Metformin Hcl11$10,150
Breo ElliptaFluticasone/Vilanterol17$7,513
Fluticasone Propionate HfaFluticasone Propionate12$2,097
Atorvastatin Calcium158$1,387
Rosuvastatin Calcium82$1,119
Losartan Potassium93$1,026
Gabapentin54$862
Pantoprazole Sodium31$719
Levothyroxine Sodium44$676
Albuterol Sulfate HfaAlbuterol Sulfate31$637
Duloxetine Hcl15$620
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide16$477
Potassium Chloride19$456

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$601$35,30128 claims
MerckJanuvia, Janumet$319$32,64637 claims
GSKBreo Ellipta$78$7,51317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →